Compare Recursion Pharmaceuticals Inc (RXRX) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs United Microelectronics Corp — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while United Microelectronics Corp trades at $21.63 (market cap $51.00B). The key difference: United Microelectronics Corp is far larger — about 33.3× Recursion Pharmaceuticals Inc's market cap, and United Microelectronics Corp pays a 2.03% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | UMC | |
|---|---|---|
Market Cap | $1.53B | $51.00B |
Sector | Health | Technology |
52-Week High | $6.79 | $28.02 |
52-Week Low | $2.84 | $6.58 |
Enterprise Value | $946.50M | $48.57B |
Dividend Yield | — | 2.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
UMC trades at $21.19, down 0.28% on the day, with a bullish technical signal from oscillators but bearish moving averages. The company reported Q1 2026 EPS of $0.20, beating expectations, and maintains a net income margin of 20.25%. Recent news highlights mass production of silicon photonics ICs and strong June 2026 sales growth of 22.85% year-over-year.
Outlook is supported by earnings beats and specialty technology demand, but risks include valuation above sector peers and competitive pressures. Analysts are mixed with 26.67% buy ratings, suggesting cautious optimism amid solid execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
